JP7445946B2 - 性質変化方法及びプラズマ生成装置 - Google Patents
性質変化方法及びプラズマ生成装置 Download PDFInfo
- Publication number
- JP7445946B2 JP7445946B2 JP2019109476A JP2019109476A JP7445946B2 JP 7445946 B2 JP7445946 B2 JP 7445946B2 JP 2019109476 A JP2019109476 A JP 2019109476A JP 2019109476 A JP2019109476 A JP 2019109476A JP 7445946 B2 JP7445946 B2 JP 7445946B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- ozone
- oxygen
- immune cells
- supplied
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 38
- 230000008859 change Effects 0.000 title description 7
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 70
- 239000001301 oxygen Substances 0.000 claims description 50
- 229910052760 oxygen Inorganic materials 0.000 claims description 50
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 45
- 210000002865 immune cell Anatomy 0.000 claims description 40
- 230000004913 activation Effects 0.000 claims description 17
- 239000003054 catalyst Substances 0.000 claims description 17
- 238000000354 decomposition reaction Methods 0.000 claims description 17
- 229910021645 metal ion Inorganic materials 0.000 claims description 12
- 239000012190 activator Substances 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 50
- 210000004027 cell Anatomy 0.000 description 31
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 18
- 229910001882 dioxygen Inorganic materials 0.000 description 18
- 238000010586 diagram Methods 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 108010074328 Interferon-gamma Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000008070 Interferon-gamma Human genes 0.000 description 8
- 229960003130 interferon gamma Drugs 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 239000000919 ceramic Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005931 immune cell recruitment Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- 230000014828 interferon-gamma production Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910000510 noble metal Inorganic materials 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Images
Landscapes
- Physical Or Chemical Processes And Apparatus (AREA)
- Plasma Technology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本実施形態に係る性質変化方法について、図1ないし図5を用いて説明する。本実施形態に係る性質変化方法は、例えば免疫細胞にオゾン分解触媒を介してオゾン(O3)を供給することで、免疫細胞を刺激し活性化するものである。オゾン(O3)はオゾン分解触媒を介することでO3→O2+O*となり、この活性酸素(O*)が免疫細胞に供給されることで免疫細胞を効率的に活性化又は不活化することができる。
(1)細菌やウイルスや細胞を貧食した樹状細胞やマクロファージの抗原提示
(2)人工的に抗原を貪食させた樹状細胞やマクロファージの抗原提示
(3)T細胞上のCD3/CD28TCRと結合可能なモノクローナル抗体を付加した微粒子の付与
(4)サイトカイン、IFN-γ(gamma)、IL-2、IL-4の付与
11 免疫細胞
12 オゾン(O3)供給源
31 酸素ガスボンベ
32 水ボトル
33 プラズマ生成装置
33a 投入口
33b 流出口
34 電源部
41 接地電極
42 セラミックチューブ
43 コイル電極
Claims (3)
- 活性因子により予め弱い活性化状態又は活性化しやすい状態になっている免疫細胞が金属イオンを含む溶液中に浸漬されており、当該溶液の表面にオゾン(O3)を供給し、当該溶液表面でオゾン分解触媒である前記金属イオンを介して前記オゾン(O3)を活性酸素(O*)に分解し、当該活性酸素(O*)を前記免疫細胞に供給して活性化させることを特徴とする性質変化方法。
- 請求項1に記載の性質変化方法において、
前記溶液の表面に供給されるオゾン(O 3 )が、
少なくとも活性化される前記免疫細胞の増加を促進する一の放電電圧、又は、当該一の放電電圧よりも高い放電電圧であって、少なくとも活性化される前記免疫細胞の増加を抑制する他の放電電圧、で発生する酸素プラズマから生成されるオゾン(O 3 )であることを特徴とする性質変化方法。 - 請求項2に記載の性質変化方法において、
前記溶液の表面に供給されるオゾン(O 3 )が、前記他の放電電圧で発生する酸素プラズマから生成されるオゾン(O 3 )である場合に、
前記免疫細胞の活性化は、当該免疫細胞の増加を抑制すると共にサイトカインの産生を促進する活性化であることを特徴とする性質変化方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019109476A JP7445946B2 (ja) | 2019-06-12 | 2019-06-12 | 性質変化方法及びプラズマ生成装置 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019109476A JP7445946B2 (ja) | 2019-06-12 | 2019-06-12 | 性質変化方法及びプラズマ生成装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020198840A JP2020198840A (ja) | 2020-12-17 |
JP7445946B2 true JP7445946B2 (ja) | 2024-03-08 |
Family
ID=73741504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019109476A Active JP7445946B2 (ja) | 2019-06-12 | 2019-06-12 | 性質変化方法及びプラズマ生成装置 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP7445946B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7328557B2 (ja) | 2020-11-30 | 2023-08-17 | 日亜化学工業株式会社 | 光源、光源装置および光源の製造方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002523332A (ja) | 1998-07-30 | 2002-07-30 | ヴァソゲン アイルランド リミテッド | 移植片対宿主病の阻止 |
JP2006199540A (ja) | 2005-01-20 | 2006-08-03 | Kansai Electric Power Co Inc:The | 第三物質触媒電極によるオゾン発生方法および発生装置 |
JP2013063368A (ja) | 2011-09-15 | 2013-04-11 | Fukuoka Institute Of Technology | 促進酸化処理方法 |
JP2014038084A (ja) | 2012-05-22 | 2014-02-27 | Reinhausen Plasma Gmbh | 耐候性試験方法および耐候性試験装置 |
-
2019
- 2019-06-12 JP JP2019109476A patent/JP7445946B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002523332A (ja) | 1998-07-30 | 2002-07-30 | ヴァソゲン アイルランド リミテッド | 移植片対宿主病の阻止 |
JP2006199540A (ja) | 2005-01-20 | 2006-08-03 | Kansai Electric Power Co Inc:The | 第三物質触媒電極によるオゾン発生方法および発生装置 |
JP2013063368A (ja) | 2011-09-15 | 2013-04-11 | Fukuoka Institute Of Technology | 促進酸化処理方法 |
JP2014038084A (ja) | 2012-05-22 | 2014-02-27 | Reinhausen Plasma Gmbh | 耐候性試験方法および耐候性試験装置 |
Also Published As
Publication number | Publication date |
---|---|
JP2020198840A (ja) | 2020-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lu et al. | Transcutaneous plasma stress: From soft-matter models to living tissues | |
Azzariti et al. | Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells | |
Cifra et al. | Electromagnetic cellular interactions | |
Konchekov et al. | Properties and use of water activated by plasma of piezoelectric direct discharge | |
JP2003531875A (ja) | 増強型追跡可能免疫化飲用水およびその他の液体および気体製品の製造方法、その製造および使用のための装置、並びに、生物を免疫するための増強型製品の使用 | |
JP2012519483A (ja) | 細胞を処理するための装置および方法 | |
US3043982A (en) | Device for the treatment of blood or the like | |
JP7445946B2 (ja) | 性質変化方法及びプラズマ生成装置 | |
RU2670654C9 (ru) | Способ получения дезинфицирующего агента и устройство для его осуществления | |
Kobzev et al. | Effect of cold plasma on the E. coli cell wall and plasma membrane | |
Martusevich et al. | Effect of cold helium plasma on oxidative metabolism and crystallogenic properties of rat blood | |
JP6372096B2 (ja) | 酵母の増殖方法および酵母の生産方法および酵母の生菌数の制御方法 | |
Recek et al. | Microplasma induced cell morphological changes and apoptosis of ex vivo cultured human anterior lens epithelial cells–relevance to capsular opacification | |
Gholami et al. | In vivo assessment of APPJ discharge on the earthworm: coelomic TAC and MDA levels, cell death, and tissue regeneration | |
JP4386650B2 (ja) | 殺菌装置 | |
Lupu et al. | Cold atmospheric plasma jet effects on V79-4 cells | |
Vladimirsky et al. | Mechanisms of signal transduction in cells facts and hypotheses | |
RU2254143C2 (ru) | Способ стерилизации объектов | |
Hayase et al. | The enhancement of Th1 immunity and the suppression of tumour growth by low-dose γ-radiation | |
CN107889772A (zh) | 一种基于等离子照射的促进养殖鱼生长方法及装置 | |
JP5797077B2 (ja) | キノコの栽培方法 | |
RU2739196C2 (ru) | Способ инициации гибели опухолевых клеток янтарной кислотой и ВЧ- и СВЧ-энергией волнового излучения | |
Subaedah et al. | Growth comparison between lymphocyte bw5147 t cells and el4 t cells using atmospheric oxygen plasma irradiation | |
Pinton et al. | Specific low frequency electromagnetic fields induce epigenetic and functional changes in U937 cells | |
Biazar et al. | Delivery Systems for Plasma-reactive Species and their Applications in the Field of Biomedicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220609 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230412 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230425 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230623 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230801 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231219 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7445946 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |